Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 10;11(12):1347. doi: 10.3390/jpm11121347

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Comparison of first (V1) and second (V2) extractions within CD4⁺ and CD8⁺ T lymphocytes, and CD19⁺ B lymphocytes subpopulations in RRMS patients under Natalizumab treatment in SD or EID. Percentage of expression of in several CD4⁺ and CD8⁺ T lymphocytes, and CD19⁺ B lymphocytes subsets. Each dot represents the percentage of expression for each marker regarding their parent population (CD4⁺ or CD8⁺ T lymphocytes, or CD19⁺ B lymphocytes populations) in the SD (n = 8) and EID (n = 21) groups. CM, Central Memory; DN, Double Negative; EID, extended interval dosing; EM, Effector Memory; NS, Non-Switched; NTZ, natalizumab; SD, standard dosing. ns: p > 0.05.